Wacker Chemie AG

WCH

Equity

ISIN DE000WCH8881 / Valor 2493384

Xetra (2025-10-17)

EUR 66.60+1.45%

Wacker Chemie AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Wacker Chemie AG is a global chemical company headquartered in Munich, Germany, known for its diverse portfolio in the chemical industry. The company operates in several key segments, including silicones, polymers, biosolutions, and polysilicon. In the biosolutions sector, Wacker Chemie AG serves as a full-service contract manufacturer, specializing in the production of plasmid DNA (pDNA), messenger ribonucleic acid (mRNA) including lipid nanoparticles (LNPs), therapeutic proteins, live biotherapeutic products (LBPs), and vaccines utilizing microbial systems. This focus on biotechnological applications highlights Wacker's commitment to advancing healthcare and life sciences through innovative chemical solutions. The company's extensive expertise and capabilities in these areas position it as a significant player in the global chemical and biotechnology markets.

Summarized from source with an LLMView SourceSector: Industrials

Sales Performance

Group sales for the first half of 2025 totaled €2.89 billion, marking a 2% decrease compared to the same period in 2024. The decline was influenced by lower volumes in solar-grade polysilicon and reduced plant utilization rates.

Profitability Metrics

EBITDA fell to €234 million, representing a 26% year-over-year decrease. EBIT was negative at €–19 million, and the net income for the period stood at €–23 million, reflecting the company's struggles in maintaining profitability.

Capital Expenditures and Cash Flow

Capital expenditures excluding acquisitions decreased by 36% to €189 million. Net cash flow remained negative at €–302 million, primarily due to the lower net income reported in the first half of 2025.

Revised Full-Year Outlook

Wacker Chemie AG has revised its full-year outlook for 2025, expecting group sales to range between €5.5 billion and €5.9 billion, down from the previous guidance of €6.1 billion to €6.4 billion. EBITDA is now anticipated to fall within €500 million to €700 million, revised down from €700 million to €900 million.

Summarized from source with an LLMView Source

Key figures

-21.2%1Y

-36.1%3Y

-28.8%5Y

Performance

41.3%1Y

38.0%3Y

38.7%5Y

Volatility